The DOI matches its Crossref record.
DNA Vaccines Expressing either the GP or NP Genes of Ebola Virus Protect Mice from Lethal Challenge
Open accessAbstract
DNA vaccines expressing the envelope glycoprotein (GP) or nucleocapsid protein (NP) genes of Ebola virus were evaluated in adult, immunocompetent mice. The vaccines were delivered into the skin by particle bombardment of DNA-coated gold beads with the Powderject-XR gene gun. Both vaccines elicited antibody responses as measured by ELISA and elicited cytotoxic T cell responses as measured by chromium release assays. From one to four vaccinations with 0.5 microgram of the GP DNA vaccine resulted in a dose-dependent protection from Ebola virus challenge. Maximal protection (78% survival) was achieved after four vaccinations. Mice were completely protected with a priming dose of 0.5 microgram of GP DNA followed by three or four subsequent vaccinations with 1.5 micrograms of DNA. Partial protection could be observed for at least 9 months after three immunizations with 0.5 microgram of the GP DNA vaccine. Comparing the GP and NP vaccines indicated that approximately the same level of protection could be achieved with either vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Novel mechanisms and devices to enable successful transdermal drug delivery
Barry, B. W. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00167-1 · Cited by 1,240
Hemorrhagic Fever Viruses as Biological Weapons: Medical and Public Health Management
Borio, L., Inglesby, T., Peters, C. J., Schmaljohn, A. L., Hughes, J. M., Jahrling, P. B., Ksiazek, T., Johnson, K. M., Meyerhoff, A., O'Toole, T., et al. (2002) · JAMA · doi:10.1001/jama.287.18.2391 · Cited by 672
Self-citationDevelopment of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Bavari, S., Bosio, C. M., Wiegand, E., Ruthel, G., Will, A. B., Geisbert, T. W., Hevey, M., Schmaljohn, C., Schmaljohn, A., & Aman, M. J. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011500 · Cited by 432
Self-citationEbola virus: from discovery to vaccine
Feldmann, H., Jones, S., Klenk, H.-D., & Schnittler, H.-J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1154 · Cited by 308
Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection
Maruyama, T., Rodriguez, L. L., Jahrling, P. B., Sanchez, A., Khan, A. S., Nichol, S. T., Peters, C. J., Parren, P. W. H. I., & Burton, D. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.6024-6030.1999 · Cited by 293
Self-citationEbola Virus VP40-Induced Particle Formation and Association with the Lipid Bilayer
Jasenosky, L. D., Neumann, G., Lukashevich, I., & Kawaoka, Y. (2001) · Journal of Virology · doi:10.1128/jvi.75.11.5205-5214.2001 · Cited by 286
Marburg Virus Vaccines Based upon Alphavirus Replicons Protect Guinea Pigs and Nonhuman Primates
Hevey, M., Negley, D., Pushko, P., Smith, J., & Schmaljohn, A. (1998) · Virology · doi:10.1006/viro.1998.9367 · Cited by 262
Self-citationWarfield, K. L., Swenson, D. L., Olinger, G. G., Kalina, W. V., Aman, M. J., & Bavari, S. (2007) · The Journal of Infectious Diseases · doi:10.1086/520583 · Cited by 260
Persistent infection with Ebola virus under conditions of partial immunity
Gupta, M., Mahanty, S., Greer, P., Towner, J. S., Shieh, W.-J., Zaki, S. R., Ahmed, R., & Rollin, P. E. (2004) · Journal of Virology · doi:10.1128/jvi.78.2.958-967.2004 · Cited by 85
Metadata
- Authors
- Vanderzanden, L., Bray, M., Fuller, D., Roberts, T., Custer, D., Spik, K., Jahrling, P., Huggins, J., Schmaljohn, A., & Schmaljohn, C.
- Venue
- Virology
- Publisher
- Elsevier BV
- Published
- 1998-06
- Volume
- 246
- Issue
- 1
- Pages
- 134-144
- ISSN
- 0042-6822 (ISSN-L)
- OpenAlex
- W1970419353
- Cited by
- 172
- References
- 0
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.